February 24, 2025
Dr. Gregory George MD PhD Joins Mesoblast Board
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
Pharmaceuticals, Biotechnology and Life Sciences
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
• Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF-β) in…
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease New detailed data from the RELIEVE…
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ETNew detailed data from the RELIEVE UCCD study support…
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) — ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating…
Approximately five months after launch, the inclusion of neffy on these three additional formularies has expanded access to half of…
IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a…
BANGKOK, Feb. 21, 2025 (GLOBE NEWSWIRE) — NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”) today issued a clarification…
RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) — BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing…
Phoenix Molecular Designs Infographic Introduction to PhoenixMD PMD-026 is a first-in-class and best-in-class pan-RSK inhibitorFavorable mPFS demonstrated in Phase 1/1b…